Section Arrow
ORKA.NASDAQ
- Oruka Therapeutics Inc
Quotes are at least 15-min delayed:2026/06/10 08:05 EDT
Pre Market
Last
 66.5224
-0.4076 (-0.61%)
Bid
65.2
Ask
66.72
High 67.57 
Low 66 
Volume 857 
Regular Hours (Closed)
Last
 66.93
+2.87 (+4.48%)
Day High 
67.125 
Prev. Close
64.06 
1-M High
67.7699 
Volume 
1.57M 
Bid
65.2
Ask
66.72
Day Low
62.55 
Open
64.91 
1-M Low
53.62 
Market Cap 
3.86B 
Currency 美元 
P/E -- 
%Yield 67.21 
10-SMA 58.75 
20-SMA 60.13 
50-SMA 62.1 
52-W High 91 
52-W Low 10.77 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.93/-2.56
Enterprise Value
3.86B
Balance Sheet
Book Value Per Share
8.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0289-0.021-42.08%-- 
Pre Market 0.0208 -0.0081 -28.03%
NUVLNuvalent123.25+34.76+39.28%-- 
Pre Market 123.25 0 0.00%
RXRXRecursion Pharmaceuticals3.22-0.1-3.01%-- 
Pre Market 3.1105 -0.1095 -3.40%
GERNGeron Corp1.12-0.01-0.88%-- 
Pre Market 1.12 0 0.00%
GOSSGossamer Bio0.16-0.0056-3.38%-- 
Pre Market 0.161 +0.001 +0.63%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and otherconditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.